Exane Derivatives’s Zogenix, Inc. ZGNX Stock Holding History

Exane Derivatives’s Portfolio ZGNX Stock Details ZGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,921	Closed	-$96.1K	–	1099
2021 Q1	$96.1K	Sell	4,921 -453	-8%	-$9.29K	0.03%	426
2020 Q4	$107K	Buy	5,374 +1,210	+29%	+$24.7K	0.03%	387
2020 Q3	$74.7K	Sell	4,164 -196	-4%	-$4.8K	0.02%	341
2020 Q2	$118K	Hold	4,360	–	–	0.03%	274
2020 Q1	$108K	Buy	+4,360	New	+$159K	0.03%	274

Other funds holding ZGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return

Exane Derivatives's ZGNX Position: Q2 2021 in Review

Exane Derivatives sold out of Zogenix, Inc. (ZGNX) in Q2 2021, closing a stake of 4,921 shares — an estimated $96.1K sold.

Exane Derivatives first reported a position in ZGNX in Q1 2020 and held it in 5 quarters. The position peaked at $118K in Q2 2020. 149 funds tracked by Wall St. Rank hold ZGNX as of Q2 2021.

Exane Derivatives reported no remaining Zogenix, Inc. position as of Q2 2021 after selling out during the quarter.
Exane Derivatives sold 4,921 Zogenix, Inc. shares in Q2 2021, an estimated $96.1K.
Exane Derivatives first reported a position in Zogenix, Inc. in Q1 2020 and held it in 5 quarters.
Exane Derivatives's Zogenix, Inc. position peaked at $118K in Q2 2020.
149 funds tracked by Wall St. Rank held Zogenix, Inc. as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.